- In this large retrospective study of infants receiving live attenuated rotavirus vaccine vs placebo, having received vaccine was associated with lower incidence of celiac disease (CD).
- Authors: “we propose that it is the intestinal damage associated with wild-type RV (rotavirus), but not RV infection as such, that triggers CD.”
Why this matters
- Some evidence suggests RV could trigger type 1 diabetes (T1D) and/or CD because of molecular mimicry.
- If it does, live attenuated oral RV vaccine could either have the same effect or, conversely, could be protective by preventing wild-type infection.
- 5764 responded to questionnaire.
- RotaTeq vs placebo groups:
- T1D prevalence: 1.04% vs 0.97% (P=.810).
- CD prevalence: 0.60% (95% CI, 0.38%-0.93%) vs 1.11% (95% CI, 0.78%-1.6%; P=.027).
- Retrospective analysis, randomized controlled double-blind REST trial plus Finnish Extension Study surveillance (n=5764).
- In REST (2001-2003), participants randomly assigned to RotaTeq (Kenilworth, NJ) vaccine vs placebo.
- In 2015, researchers sent questionnaire to parents of 19,133 Finnish Extension Study participants, asking about T1D, CD diagnoses.
- Outcome: T1D and CD prevalence at time of questionnaire.
- Funding: None disclosed.
- Apparent lack of vaccine effect on T1D could also be explained by its having similar effect to wild-type virus.
- Low questionnaire response rate.